RS50743B - Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama - Google Patents

Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama

Info

Publication number
RS50743B
RS50743B YUP-710/02A YUP71002A RS50743B RS 50743 B RS50743 B RS 50743B YU P71002 A YUP71002 A YU P71002A RS 50743 B RS50743 B RS 50743B
Authority
RS
Serbia
Prior art keywords
factor viii
vector
mutein
viii mutein
amino acid
Prior art date
Application number
YUP-710/02A
Other languages
English (en)
Serbian (sr)
Inventor
Charlotte Hauser
Andrea Hörster
Carola Schröder
Michael Lehnerer
Original Assignee
OCTAPHARMA BIOPHARMACEUTICALS GmbH.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00106225A external-priority patent/EP1136553A1/en
Application filed by OCTAPHARMA BIOPHARMACEUTICALS GmbH. filed Critical OCTAPHARMA BIOPHARMACEUTICALS GmbH.
Publication of YU71002A publication Critical patent/YU71002A/sh
Publication of RS50743B publication Critical patent/RS50743B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
YUP-710/02A 2000-03-22 2001-03-21 Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama RS50743B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00106225A EP1136553A1 (en) 2000-03-22 2000-03-22 Production of recombinant blood clotting factors in human cell lines
US20324900P 2000-05-08 2000-05-08

Publications (2)

Publication Number Publication Date
YU71002A YU71002A (sh) 2005-11-28
RS50743B true RS50743B (sr) 2010-08-31

Family

ID=26070708

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-710/02A RS50743B (sr) 2000-03-22 2001-03-21 Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama

Country Status (28)

Country Link
US (1) US7572619B2 (enExample)
EP (2) EP1266006B1 (enExample)
JP (1) JP3894795B2 (enExample)
KR (1) KR100581574B1 (enExample)
CN (1) CN1454257B (enExample)
AT (1) ATE312176T1 (enExample)
AU (3) AU2001254715B2 (enExample)
BE (1) BE2014C077I2 (enExample)
BG (1) BG65930B1 (enExample)
BR (1) BRPI0109494B8 (enExample)
CA (1) CA2404163C (enExample)
CZ (1) CZ303929B6 (enExample)
DE (1) DE60115613T2 (enExample)
DK (1) DK1266006T3 (enExample)
EA (1) EA004317B1 (enExample)
EE (1) EE200200538A (enExample)
ES (1) ES2254403T3 (enExample)
FR (1) FR15C0003I2 (enExample)
HR (1) HRP20020767B1 (enExample)
HU (1) HU228091B1 (enExample)
IL (2) IL151857A0 (enExample)
MX (1) MXPA02009221A (enExample)
NO (1) NO330910B1 (enExample)
NZ (1) NZ521732A (enExample)
RS (1) RS50743B (enExample)
SI (1) SI1266006T1 (enExample)
SK (1) SK287706B6 (enExample)
WO (1) WO2001070968A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1266006T1 (sl) * 2000-03-22 2006-06-30 Octagene Gmbh Proizvodnja rekombinantnih muteinov krvnega koagulacijskega faktorja VIII v humanih celicnih linijah
WO2002024723A1 (en) * 2000-09-19 2002-03-28 Emory University Modified factor viii
EP1469064A1 (en) 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression of proteins in endothelial cells derived from precursor cells from cord blood
US7425539B2 (en) 2004-03-19 2008-09-16 Baxter International Inc. Factor IXa for the treatment of bleeding disorders
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
ES2436741T3 (es) 2004-09-22 2014-01-07 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CN101120085B (zh) * 2005-02-11 2011-06-08 诺和诺德医疗保健公司 在包含植物蛋白水解产物的无血清细胞培养液中生产多肽
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
ES2440487T3 (es) 2006-07-13 2014-01-29 Wyeth Llc Producción de glucoproteínas
CA3090908A1 (en) * 2007-04-26 2008-11-06 Aptevo Biotherapeutics Llc Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
EP2198870A4 (en) * 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp ACTIVATOR FOR BLOOD CREATION FACTOR VII PROMOTER AND ITS USE
BRPI0917656A2 (pt) 2008-08-21 2017-07-11 Octapharma Ag Fatores viii e ix humanos produzidos de forma recombinante
SG2014012918A (en) 2009-02-11 2014-04-28 Novozymes Biopharma Dk As Albumin variants and conjugates
CA2776503C (en) 2009-10-02 2020-07-28 The Children's Hospital Of Philadelphia Compositions and methods for enhancing coagulation factor viii function
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
BRPI1105317A2 (pt) * 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
CN102199607B (zh) * 2011-03-30 2012-11-14 山西大学 重组人凝血因子ix小基因及其ptc突变体稳定细胞株
EP3626737B1 (en) 2011-05-13 2023-11-29 Octapharma AG A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
TWI687441B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
CN102321668A (zh) * 2011-07-06 2012-01-18 中国人民解放军军事医学科学院野战输血研究所 一种表达重组人凝血因子ⅶ的方法及其专用载体
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
US9394353B2 (en) 2011-10-18 2016-07-19 Csl Limited Method for improving the stability of purified factor VIII after reconstitution
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
EP2787081A4 (en) 2011-11-30 2015-10-07 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
WO2014008172A2 (en) * 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
JP6487328B2 (ja) 2012-11-08 2019-03-20 アルブミディクス リミティド アルブミン変異体
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
EP2853538A1 (en) 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analogues of temporin-SHa and uses thereof
ES2883158T3 (es) 2014-07-30 2021-12-07 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
AP2017009828A0 (en) 2014-10-31 2017-03-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
AR104956A1 (es) 2015-06-09 2017-08-30 Glycotope Gmbh MÉTODO MEJORADO PARA LA PRODUCCIÓN DE POLIPÉPTIDOS g-CARBOXILADOS
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
SG11201808422QA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Gene therapy for treating hemophilia a
TW202300168A (zh) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
WO2020020364A1 (zh) * 2018-07-26 2020-01-30 正大天晴药业集团南京顺欣制药有限公司 一种制备重组人凝血因子ⅷ的方法
SG10202106830VA (en) 2018-08-10 2021-08-30 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
WO2020086686A2 (en) 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
US12473353B2 (en) 2019-05-15 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule, a pharmaceutical composition, and a method
CA3221235A1 (en) 2021-06-11 2022-12-15 Ali Ladram Short antimicrobial peptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS6171774A (ja) * 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
EP0218713B1 (en) 1985-04-22 1992-03-25 Genetics Institute, Inc. High yield production of active factor ix
WO1987004187A1 (en) * 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5024939A (en) 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
JP2865861B2 (ja) * 1989-11-17 1999-03-08 ノボ ノルディスク アクティーゼルスカブ 第▲ｖｉｉｉ▼：ｃ因子活性を有するタンパク質複合体およびその製法
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
ES2052368T3 (es) 1990-01-26 1994-07-01 Immuno Ag Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso.
US5445953A (en) * 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
JPH08511423A (ja) * 1993-06-10 1996-12-03 ジェネティック セラピー，インコーポレイテッド 血友病治療のためのアデノウイルスベクター
EP0915975A2 (en) * 1996-07-03 1999-05-19 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
CA2362970A1 (en) * 1999-02-19 2000-08-24 Octagene Gmbh Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
AU6770200A (en) * 1999-08-13 2001-03-13 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2domain in the presence or absence of a bound ligand and methods of use thereof
SI1266006T1 (sl) * 2000-03-22 2006-06-30 Octagene Gmbh Proizvodnja rekombinantnih muteinov krvnega koagulacijskega faktorja VIII v humanih celicnih linijah
WO2003009237A1 (en) * 2001-07-18 2003-01-30 Skaginn Hf. A method and apparatus for relating information of a processed object to an operator

Also Published As

Publication number Publication date
DE60115613D1 (de) 2006-01-12
US20040023333A1 (en) 2004-02-05
AU2006201848A1 (en) 2006-05-25
MXPA02009221A (es) 2005-07-25
KR100581574B1 (ko) 2006-05-22
SK287706B6 (en) 2011-07-06
BG65930B1 (bg) 2010-05-31
SI1266006T1 (sl) 2006-06-30
YU71002A (sh) 2005-11-28
NZ521732A (en) 2004-05-28
NO330910B1 (no) 2011-08-15
BE2014C077I2 (enExample) 2020-01-30
KR20030011079A (ko) 2003-02-06
ES2254403T3 (es) 2006-06-16
NO20024475L (no) 2002-11-20
NO20024475D0 (no) 2002-09-19
JP2003530093A (ja) 2003-10-14
EP1460131A2 (en) 2004-09-22
CN1454257B (zh) 2013-01-16
WO2001070968A2 (en) 2001-09-27
EE200200538A (et) 2004-04-15
HU228091B1 (en) 2012-10-29
JP3894795B2 (ja) 2007-03-22
EA200201008A1 (ru) 2003-02-27
IL151857A0 (en) 2003-04-10
IL151857A (en) 2010-05-31
CA2404163A1 (en) 2001-09-27
CZ20023166A3 (cs) 2003-02-12
ATE312176T1 (de) 2005-12-15
EP1266006B1 (en) 2005-12-07
SK15042002A3 (sk) 2003-09-11
BRPI0109494B8 (pt) 2021-05-25
AU5471501A (en) 2001-10-03
HUP0300588A3 (en) 2005-09-28
EP1266006A2 (en) 2002-12-18
US7572619B2 (en) 2009-08-11
CZ303929B6 (cs) 2013-07-03
DK1266006T3 (da) 2006-01-16
FR15C0003I1 (fr) 2015-02-27
BR0109494A (pt) 2002-12-10
CN1454257A (zh) 2003-11-05
DE60115613T2 (de) 2006-08-24
EA004317B1 (ru) 2004-02-26
HRP20020767A2 (en) 2005-02-28
HUP0300588A2 (hu) 2003-06-28
BRPI0109494B1 (pt) 2021-05-11
HRP20020767B1 (hr) 2011-09-30
FR15C0003I2 (fr) 2015-11-20
WO2001070968A3 (en) 2001-12-13
BG107152A (bg) 2003-06-30
CA2404163C (en) 2009-09-29
AU2001254715B2 (en) 2006-02-02
EP1460131A3 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
RS50743B (sr) Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama
AU2001254715A1 (en) Production of recombinant blood clotting factors in human cell lines
JP2022118129A (ja) 第ｖｉｉｉ因子キメラタンパク質及びその使用
US7122634B2 (en) Modified factor VIII
KR100642293B1 (ko) 제 8 인자 폴리펩티드
JP2022000471A (ja) ＸＴＥＮおよびｖｏｎ Ｗｉｌｌｅｂｒａｎｄ因子タンパク質を有する第ＶＩＩＩ因子の複合体、および、その使用
EP0506757B1 (en) A recombinant human factor viii derivative
EP0672138B1 (en) Chimeric procoagulant proteins
US10696960B2 (en) Fusion protein having factor VII activity
CN104774269B (zh) 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
CA2068728A1 (en) Protein complexes having factor viii:c activity and production thereof
JP2872255B2 (ja) ファクター▲ｖｉｉｉ▼の高収量生産法
JP2011526151A (ja) 低下した免疫原性を有する因子ｖｉｉｉ変異タンパク質
CZ140298A3 (cs) Hybridní faktor VIII s modifikovanou aktivitou
EP1136553A1 (en) Production of recombinant blood clotting factors in human cell lines
NZ616479A (en) Complement factor b analogs and their uses